Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
|
| gptkbp:actsOn |
acetylcholinesterase reactivator
|
| gptkbp:administeredBy |
intramuscular injection
intravenous injection |
| gptkbp:affiliatedWith |
antidote
oxime |
| gptkbp:alternativeName |
gptkb:pralidoxime
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
V03AB05
|
| gptkbp:CASNumber |
94-91-7
|
| gptkbp:contraindication |
gptkb:myasthenia_gravis
|
| gptkbp:discoveredIn |
1950s
|
| gptkbp:hasMolecularFormula |
C7H9N2O
|
| gptkbp:hasUNII |
8GTS82S83M
|
| https://www.w3.org/2000/01/rdf-schema#label |
5-PAM
|
| gptkbp:IUPACName |
1-(2-hydroxyiminomethylpyridinium)propan-1-one
|
| gptkbp:molecularWeight |
137.16 g/mol
|
| gptkbp:PubChem_CID |
4908
|
| gptkbp:sideEffect |
nausea
hypertension tachycardia |
| gptkbp:usedFor |
treatment of organophosphate poisoning
|
| gptkbp:bfsParent |
gptkb:Pulse_Amplitude_Modulation_with_5_levels
|
| gptkbp:bfsLayer |
7
|